ImmunoPrecise Antibodies ... (IPA)
0.44
0.01 (3.04%)
At close: Apr 17, 2025, 3:59 PM
ImmunoPrecise Antibodies Revenue Breakdown
| Period Ending | Apr 30, 2024 |
|---|---|
| Product Sales Revenue | 2.04M |
| Product Sales Revenue Growth | n/a |
| Project Revenue Revenue | 22.23M |
| Project Revenue Revenue Growth | n/a |
Revenue by Geography
| Period Ending | Apr 30, 2024 | Apr 30, 2023 | Apr 30, 2022 |
|---|---|---|---|
| Australia Revenue | 482K | 630K | 1.54M |
| Australia Revenue Growth | -23.49% | -59.09% | n/a |
| All Other Countries Revenue | 224K | 602K | 1.01M |
| All Other Countries Revenue Growth | -62.79% | -40.22% | n/a |
| Canada Revenue | 389K | 618K | 572K |
| Canada Revenue Growth | -37.06% | +8.04% | n/a |
| Europe Revenue | 10.87M | 9.45M | 9.43M |
| Europe Revenue Growth | +14.99% | +0.22% | n/a |
| United States Revenue | 12.56M | 9.37M | 6.82M |
| United States Revenue Growth | +34.07% | +37.40% | n/a |
Operating Expense Breakdown
| Period Ending | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 | Aug 9, 2023 | Apr 30, 2023 | Jan 31, 2023 | Dec 13, 2022 | Jul 31, 2022 | Apr 30, 2022 | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 | Jan 31, 2021 | Oct 31, 2020 | Jul 31, 2020 | Apr 30, 2020 | Jan 31, 2020 | Oct 31, 2019 | Jul 31, 2019 | Apr 30, 2019 | Jan 31, 2019 | Oct 31, 2018 | Jul 31, 2018 | Apr 30, 2018 | Jan 31, 2018 | Oct 31, 2017 | Jul 31, 2017 | Apr 30, 2017 | Jan 31, 2017 | Oct 31, 2016 | Jul 31, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 4.51M | 4.88M | 5.03M | 4.83M | 4.23M | 5.24M | 7.6M | 5.48M | 5.09M | 5.24M | 5.87M | 4.17M | 3.63M | 4.04M | 4.53M | 3.88M | 2.91M | 2.02M | 2.87M | 1.14M | 2.23M | 2.09M | 1.92M | 2.16M | 2.26M | 2.12M | 2.23M | 1.92M | 1.23M | 1.16M | 1.23M | 4.78M | 241.22K | 370.34K | 4.11K | 15.78K | 2.4K | 4.67K | 8.18K |
| Selling, General, and Administrative Revenue Growth | -7.60% | -2.92% | +4.16% | +14.14% | -19.28% | -31.04% | +38.66% | +7.64% | -2.84% | -10.75% | +40.90% | +14.80% | -10.28% | -10.71% | +16.79% | +33.18% | +44.34% | -29.75% | +152.48% | -49.03% | +7.00% | +8.59% | -11.09% | -4.60% | +6.68% | -4.86% | +16.24% | +56.63% | +5.65% | -5.96% | -74.17% | +1879.70% | -34.86% | +8919.43% | -73.98% | +556.72% | -48.51% | -42.96% | n/a |
| Research and Development Revenue | 1.16M | 1.64M | 927K | 1M | 1.04M | 5.78M | 502K | 1.03M | 4.56M | 5.78M | 906K | 1.82M | 2.85M | 1.12M | 615.47K | n/a | 1.05M | 309.21K | -221.01K | 54.19K | 445.84K | 167.26K | 188.65K | 60.05K | 19.27K | 31.79K | 385.5K | 64.68K | 118.93K | 106.32K | 393.92K | 72.89K | n/a | 59.22K | 417.7K | 59.55K | 61.68K | 49.81K | n/a |
| Research and Development Revenue Growth | -29.66% | +77.13% | -7.39% | -3.47% | -82.05% | +1051.00% | -51.36% | -77.37% | -21.08% | +537.75% | -50.22% | -36.10% | +154.51% | +81.81% | n/a | -100.00% | +239.35% | -239.91% | -507.85% | -87.85% | +166.56% | -11.34% | +214.16% | +211.68% | -39.39% | -91.75% | +495.99% | -45.61% | +11.86% | -73.01% | +440.41% | n/a | -100.00% | -85.82% | +601.39% | -3.45% | +23.84% | n/a | n/a |
| Sales and Marketing Revenue | 1.24M | 718K | 909K | 649K | 921K | 311K | 934K | 836K | 817K | 311K | 151K | 228K | 198K | 163K | 186.19K | 215.9K | 255.6K | 33.31K | 151.46K | 48.12K | 60.95K | 117.2K | 139.32K | 357.29K | 268.88K | 53.77K | 19.2K | 36.38K | 46.1K | 33K | 92.87K | 17.43K | 4.89K | 4K | 4.3K | 7.12K | 5.5K | 3.91K | n/a |
| Sales and Marketing Revenue Growth | +72.28% | -21.01% | +40.06% | -29.53% | +196.14% | -66.70% | +11.72% | +2.33% | +162.70% | +105.96% | -33.77% | +15.15% | +21.47% | -12.46% | -13.76% | -15.53% | +667.43% | -78.01% | +214.78% | -21.05% | -47.99% | -15.88% | -61.01% | +32.88% | +400.06% | +180.11% | -47.24% | -21.08% | +39.70% | -64.47% | +432.92% | +256.31% | +22.21% | -6.97% | -39.54% | +29.29% | +40.74% | n/a | n/a |